Last A$0.08 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 12:54 AM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

phosphagenics ltd (POH) Snapshot

Open
A$0.08
Previous Close
A$0.08
Day High
A$0.08
Day Low
A$0.08
52 Week High
10/24/13 - A$0.16
52 Week Low
10/13/14 - A$0.07
Market Cap
97.2M
Average Volume 10 Days
1.1M
EPS TTM
A$-0.0092
Shares Outstanding
1.3B
EX-Date
08/22/97
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHOSPHAGENICS LTD (POH)

Related News

No related news articles were found.

phosphagenics ltd (POH) Related Businessweek News

No Related Businessweek News Found

phosphagenics ltd (POH) Details

Phosphagenics Limited, a biotechnology company, produces, sells, and licenses products for the pharmaceutical, cosmetics, and animal health industries. It is involved in the commercialization of drug delivery applications based on its transdermal Targeted Penetration Matrix (TPM) technology that is used to deliver pharmaceutical and nutraceutical products. Its Skin Care segment provides a range of products to enhance the appearance of skin. The company’s Pain Portfolio segment focuses on enhancing the delivery of opioids used for pain treatment through the skin. Phosphagenics Limited serves various customers in Australia, Germany, Switzerland, and the United States. The company was formerly known as Vital Capital Limited and changed its name to Phosphagenics Limited in 2004. Phosphagenics Limited is headquartered in Clayton, Australia.

35 Employees
Last Reported Date: 02/28/14

phosphagenics ltd (POH) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: A$412.6K
Chief Financial Officer
Total Annual Compensation: A$145.2K
General Counsel
Total Annual Compensation: A$204.2K
Vice President of Bioanalytical and CMC
Total Annual Compensation: A$155.6K
General Manager of Personal Care
Total Annual Compensation: A$151.0K
Compensation as of Fiscal Year 2013.

phosphagenics ltd (POH) Key Developments

Phosphagenics Limited Reports Audited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Phosphagenics Limited reported audited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported total revenue of AUD 712,000 against AUD 929,000 a year ago. Loss before income tax was AUD 2,785,000 against AUD 6,072,000 a year ago. Loss after income tax was AUD 2,785,000 or 0.27 cents per basic and diluted share against AUD 6,072,000 or 0.59 cents per basic and diluted share a year ago. Net cash out flow from operating activities was AUD 1,170,000 against AUD 2,820,000 a year ago. Purchase of plant and equipment was AUD 13,000 against AUD 31,000 a year ago. A net tangible asset per security was 1.18 cents against 1.69 cents a year ago.

Phosphagenics Completes First IND Enabling Study for TPM(R) / Oxymorphone Patch

Phosphagenics Limited announced that the first of its additional studies designed to further characterise the TPM(R)/Oxymorphone patch, in support of an Investigational New Drug (IND) application with the FDA has been completed. The study was conducted on 15 healthy volunteers at Linear Clinical Research's facility in Perth, it assessed additional pharmacokinetic parameters associated with the safety and elimination profile that were not addressed in the previous multiple dose Phase 1 study. The data generated will be used to help design the upcoming Phase 2 study, support the IND application and inform the eventual product label. This single dose study unequivocally reproduced the outstanding results obtained in the previous Phase 1 study, both in terms of the oxymorphone delivery profile from the patch and the oxymorphone blood concentration in subjects.All 15 subjects achieved an oxymorphone blood concentration that was well above the minimum therapeutic blood level for the drug. The total number of subjects exposed to the TPM(R)/Oxymorphone patch now stands at 27 with all patients attaining therapeutic oxymorphone blood levels. Phosphagenics' TPM(R)/Oxymorphone patch development program for the next 18 months was previously described at this year's Annual General Meeting and reiterated in an announcement to the market on 28 July 2014. This result represents the successful and timely completion of the first stage of additional research that was communicated to the market. Phosphagenics will shortly commence the second planned study which will compare the transdermal absorption of oxymorphone from application of the patch to different parts of the body. That study will inform the selection of appropriate sites for application of patches during Phase 2. Both characterisation studies have been designed to provide valuable information for potential licensees as well as various global regulatory bodies.

Phosphagenics Limited, Special/Extraordinary Shareholders Meeting, Aug 25, 2014

Phosphagenics Limited, Special/Extraordinary Shareholders Meeting, Aug 25, 2014. Location: RACV City Club. Agenda: To consider approval of the prior issue of securities; to consider approval of an issue of securities pursuant to a further placement.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POH:AU A$0.08 AUD 0.00

POH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $1.37 USD +0.05
View Industry Companies
 

Industry Analysis

POH

Industry Average

Valuation POH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 44.5x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 49.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHOSPHAGENICS LTD, please visit www.phosphagenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.